Published in Pharma Law Weekly, November 28th, 2006
Current study results from the report, "A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer," have been published. In this recent report, researchers in the United States conducted a study "To determine the maximum tolerated dose (MTD), dose-limiting toxicity, and pharmacokinetics of 17-allylamino-demethoxy-geldanamycin (17-AAG) administered on days 1, 4, 8, and 11 every 21 days and to examine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.